Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F. Fakih MG, et al. Among authors: modest dp. N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22. N Engl J Med. 2023. PMID: 37870968 Clinical Trial.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Prager GW, et al. Among authors: modest dp. N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. N Engl J Med. 2023. PMID: 37133585 Clinical Trial.
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Díaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhäuser G, Fisher D, Morano F, Pietrantonio F, Modest DP. Raimondi A, et al. Among authors: modest dp. Eur J Cancer. 2023 Sep;190:112945. doi: 10.1016/j.ejca.2023.112945. Epub 2023 Jun 19. Eur J Cancer. 2023. PMID: 37441940 Clinical Trial.
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer.
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Élez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Prager GW, et al. Among authors: modest dp. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100. Epub 2024 Jul 2. Future Oncol. 2024. PMID: 38953855 Free PMC article.
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series.
Platt JR, Allotey J, Alouani E, Glasbey J, Intini R, Lonardi S, Mazzoli G, Militello AM, Modest DP, Palle J, Pietrantonio F, Riyad K, Samuel L, Schulze AV, Shiu KK, Taieb J, Tolan DJM, West NP, Westwood AC, Williams CJM, Seligmann JF. Platt JR, et al. Among authors: modest dp. ESMO Open. 2024 Sep;9(9):103698. doi: 10.1016/j.esmoop.2024.103698. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241497 Free PMC article.
Minimal Invasive Versus Open Surgery for Colorectal Liver Metastases: A Multicenter German StuDoQ|Liver Registry-Based Cohort Analysis in Germany.
Moosburner S, Kettler C, Hillebrandt KH, Blank M, Freitag H, Knitter S, Krenzien F, Nevermann N, Sauer IM, Modest DP, Lurje G, Öllinger R, Schöning W, Werner J, Schmeding M, Pratschke J, Raschzok N. Moosburner S, et al. Among authors: modest dp. Ann Surg Open. 2023 Nov 2;4(4):e350. doi: 10.1097/AS9.0000000000000350. eCollection 2023 Dec. Ann Surg Open. 2023. PMID: 38144486 Free PMC article.
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
Frost N, Unger K, Blum TG, Misch D, Kurz S, Lüders H, Olive E, Raspe M, Hilbrandt M, Koch M, Böhmer D, Senger C, Witzenrath M, Grohé C, Bauer T, Modest DP, Kollmeier J. Frost N, et al. Among authors: modest dp. Lung Cancer. 2023 May;179:107184. doi: 10.1016/j.lungcan.2023.107184. Epub 2023 Mar 31. Lung Cancer. 2023. PMID: 37040677
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
Lozzi I, Arnold A, Barone M, Johnson JC, Sinn BV, Eschrich J, Gebert P, Wang R, Hu M, Feldbrügge L, Schirmeier A, Reutzel-Selke A, Malinka T, Krenzien F, Schöning W, Modest DP, Pratschke J, Sauer IM, Felsenstein M. Lozzi I, et al. Among authors: modest dp. Oncoimmunology. 2024 Oct 1;13(1):2406052. doi: 10.1080/2162402X.2024.2406052. eCollection 2024. Oncoimmunology. 2024. PMID: 39359389 Free PMC article.
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Germani MM, et al. Among authors: modest dp. J Clin Oncol. 2025 Sep 4:JCO2501003. doi: 10.1200/JCO-25-01003. Online ahead of print. J Clin Oncol. 2025. PMID: 40906970
161 results